{"nctId":"NCT00345579","briefTitle":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","startDateStruct":{"date":"2006-09"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"count":4432,"armGroups":[{"label":"Menhibrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014","Biological: Pediarix/Infanrix Penta"]},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ActHIB","Biological: Pediarix/Infanrix Penta"]}],"interventions":[{"name":"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014","otherNames":[]},{"name":"ActHIB","otherNames":[]},{"name":"Pediarix/Infanrix Penta","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects for whom the investigator believes that parents/guardians can and will comply with the requirements of the protocol.\n* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Born after 36 weeks gestation.\n* Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment.\n* Infants may have received a birth dose of Bacillus Calmette-Gu√©rin (BCG) vaccine.\n\nExclusion criteria:\n\nUse of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine(s).\n* Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and/or poliovirus; more than one previous dose of hepatitis B vaccine.\n* In country(ies) where Prevnar will be provided by GSK Biologicals, previous vaccination with Prevnar.\n* History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, hepatitis B, and/or poliovirus disease.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including dry natural latex rubber.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Acute disease at time of enrollment.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.\n* Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)","description":"NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Rash","description":"Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With New Onset of Chronic Illnesses (NOCIs)","description":"NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Rash","description":"Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Adverse Events Resulting in Emergency Room (ER)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":157,"n":3278},"commonTop":[]}}}